View in EDS

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)

Saved in:
Bibliographic Details
Title: Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)
Authors: Ciaffi, Laura, Koulla-Shiro, Sinata, Sawadogo, Adrien Bruno, Ndour, Cheik Tidiane, Eymard-Duvernay, Sabrina, Mbouyap, Pretty Rosereine, Ayangma, Liliane, Zoungrana, Jacques, Gueye, Ndeye Fatou Ngom, Diallo, Mohamadou, Izard, Suzanne, Bado, Guillaume, Kane, Coumba Toure, Aghokeng, Avelin Fobang, Peeters, Martine, Girard, Pierre Marie, Le Moing, Vincent, Reynes, Jacques, Delaporte, Eric, Calmy, Alexandra
Source: The Lancet HIV, Vol. 4, No 9 (2017) pp. e384-e392
Publisher Information: 2017.
Publication Year: 2017
Subject Terms: ddc:616, Adult, Male, Highly Active/methods, Combination/methods, Anti-HIV Agents/administration & dosage/economics/therapeutic use, HIV Infections/drug therapy/epidemiology/virology, Lamivudine/administration & dosage/therapeutic use, Antiretroviral Therapy, Cameroon/epidemiology, HIV Protease Inhibitors/administration & dosage/therapeutic use, Middle Aged, Africa South of the Sahara/epidemiology, Viral Load/drug effects, CD4 Lymphocyte Count, Drug Therapy, Senegal/epidemiology, HIV-1, Humans, Female, Reverse Transcriptase Inhibitors/administration & dosage/therapeutic use
Description: Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease inhibitor monotherapy with dual therapy with boosted protease inhibitor plus lamivudine in patients on second-line antiretrovial therapy (ART).
Document Type: Article
File Description: application/pdf
Language: English
DOI: 10.1016/s2352-3018(17)30069-3
Access URL: https://archive-ouverte.unige.ch/unige:112376
Accession Number: edsair.dedup.wf.002..a8b56a9b73adc7fcbe5c10f63493a325
Database: OpenAIRE
Description
Abstract:Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease inhibitor monotherapy with dual therapy with boosted protease inhibitor plus lamivudine in patients on second-line antiretrovial therapy (ART).
DOI:10.1016/s2352-3018(17)30069-3